Ion Exchange Q1 FY27: PAT plunges 94% YoY to ₹3 Cr as margins collapse, revenue up 20%

Consolidated PAT (the primary basis) came in at ₹3.06 Cr, down 93.7% YoY from ₹48.44 Cr and 87.4% QoQ from ₹24.29 Cr, even as consolidated revenue grew 20.1% YoY to ₹700.46 Cr (down 18.9% sequentially off a seasonally heavier Q4). Standalone tells a materially milder story — PAT fell 75.7% YoY to ₹11.40 Cr versus the consolidated 93.7% drop — a gap large enough that readers seeing either number elsewhere should not assume one is wrong; it stems from subsidiary-level losses and a ₹1.05 Cr loss attributable to non-controlling interests (owners' share of consolidated profit was ₹4.11 Cr). Net profit margin fell to 0.43% of total income from 8.06% a year ago and 2.68% last quarter. The compression is concentrated in two segments: Treatment Solutions (the renamed, reorganised former Engineering business) swung to a ₹17.35 Cr consolidated loss from a ₹16.81 Cr profit in Q1 FY26 and a smaller ₹1.19 Cr loss last quarter; Specialty Chemicals profit nearly halved YoY to ₹22.27 Cr from ₹46.25 Cr even as segment revenue grew 21.6% to ₹229.65 Cr — volume growth without margin, consistent with the input-cost pass-through problem management flagged on the May 2026 call. Consumer Products stayed loss-making but the loss narrowed to ₹0.34 Cr from ₹0.45 Cr YoY, tracking toward management's stated break-even goal. On the May 2026 (Q4 FY26) call, management said it could not yet give FY27 sales/margin guidance for the chemicals and engineering divisions given the "dynamic geopolitical situation," with clarity expected only in H2 FY27, while noting it was actively working to pass on input cost increases; it also said it expected "continued improvement in sales and margins over the next few months." This quarter delivered on the sales half of that statement but missed on margins. No analyst/consensus estimates for this specific quarter surfaced in a web search, so the print's standing versus Street is unknown; the company issued no press release alongside this filing, so there is no fresh management framing to reconcile against the numbers. Two other developments this quarter sit outside the P&L: a $52.83 Mn Hyundai order win on July 10, 2026 (a forward order-book data point for the segments currently under margin pressure) and a ₹1.25/share FY26 dividend recommendation on May 26, 2026.